Highlights

  • IperionX operated its Virginia titanium Facility on a continuous schedule during the June 2026 quarter, while reporting that HAMR powder met or exceeded grade 5 quality parameters.
  • The company is targeting approximately 200 tonnes a year of titanium powder capacity by the end of 2026, with further expansion ambitions beyond that level.
  • A newly commissioned 300-ton six-axis powder metallurgy press increased component Manufacturing capacity and supports work with defence and industrial customers.
  • US government awards provide reimbursable support for manufacturing expansion, but the company remains pre-commercial and continues to depend on external funding.
  • The Titan project adds a mineral-development pathway alongside the titanium manufacturing strategy, increasing both optionality and execution requirements.

IperionX Ltd (ASX:IPX) is developing titanium powder and component manufacturing capacity in Virginia using its HAMR and HSPT processes, while also advancing the Titan mineral project. With no meaningful commercial revenue, the 2026 focus is on production scale-up, customer qualification, government support and cash requirements.

Virginia Facility Moves Into Continuous Operations

During the June 2026 quarter, IperionX reported that its Virginia facility operated on a 24-hour, seven-day schedule. Management said HAMR titanium powder met or exceeded grade 5 quality parameters, although furnace maintenance temporarily reduced output. The company is targeting approximately 200 tonnes a year of titanium powder capacity by the end of 2026. This remains a target rather than achieved annual production.

Component Manufacturing Capacity Expands

IperionX commissioned a 300-ton, six-axis powder metallurgy press at its South Boston campus. The company stated that it can run up to 24 pressing cycles a minute and support about 11 million single-cavity parts a year. The June quarter update said the press tripled existing capacity, while two additional sintering furnaces were being installed for component production.

Customer Qualification Remains the Commercial Test

Commercial traction remains at the prototype and development stage. The June quarter update referred to US Army testing of titanium fasteners, a follow-on order for Joint Light Tactical Vehicle fastener prototypes, Carver Pump impellers under evaluation and components for Ford in production. Recurring orders and sustained volumes will still be needed to demonstrate a commercial manufacturing model.

Government Support Reduces but Does Not Remove Funding Needs

US government support is material to the scale-up program. IperionX has a US$47.1 million Industrial Base Analysis and Sustainment award and a US$12.7 million Defense Production Act Title III award. At 30 June 2026, US$37.1 million of obligated reimbursable funding remained. These programs support eligible expenditure but are not recurring commercial revenue.

Cash was US$35.2 million at 30 June 2026. In July, IperionX raised about US$50 million through American depositary shares. The raising highlights the financing risk attached to a pre-commercial business, where losses, expansion and customer qualification can require further Capital before Operating Cash Flow becomes self-sustaining.

Titan Project Adds a Second Development Pathway

The company also completed a definitive feasibility study for the Titan project. IperionX reported an after-tax net present value of US$813 million at an 8% discount rate, a 39.4% internal rate of return and a 3.6-year payback period, based on company assumptions. The project adds a mineral-development pathway alongside manufacturing, with separate permitting, construction and funding risks.

Key Insights

IperionX's 2026 progress is a scale-up story rather than an Earnings story. Continuous operations, added pressing capacity, government-backed programs and customer qualification show progress beyond laboratory development. Production targets, recurring orders and cost competitiveness still need to be demonstrated at larger scale, while cash consumption remains a central consideration.